D. Boral Capital Reaffirms Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

D. Boral Capital reiterated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report published on Monday morning,Benzinga reports. D. Boral Capital currently has a $31.00 target price on the stock.

Several other brokerages have also issued reports on NRXP. Ascendiant Capital Markets raised their target price on NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th.

NRx Pharmaceuticals Price Performance

NRx Pharmaceuticals stock opened at $2.07 on Monday. The business has a 50 day moving average of $2.77 and a 200-day moving average of $2.04. NRx Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $6.01. The company has a market capitalization of $35.02 million, a P/E ratio of -0.97 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings results on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). Equities analysts anticipate that NRx Pharmaceuticals will post -1.75 EPS for the current year.

Hedge Funds Weigh In On NRx Pharmaceuticals

A number of hedge funds have recently bought and sold shares of NRXP. AdvisorShares Investments LLC grew its holdings in NRx Pharmaceuticals by 138.5% during the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after acquiring an additional 180,229 shares during the period. Anson Funds Management LP boosted its position in shares of NRx Pharmaceuticals by 30.3% during the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock valued at $408,000 after purchasing an additional 43,135 shares in the last quarter. Millennium Management LLC acquired a new stake in NRx Pharmaceuticals during the fourth quarter worth approximately $61,000. Squarepoint Ops LLC bought a new stake in NRx Pharmaceuticals in the fourth quarter worth approximately $56,000. Finally, Townsquare Capital LLC bought a new stake in NRx Pharmaceuticals in the third quarter worth approximately $25,000. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.